FindTrial
Sign In

Fibroblast growth factor 21 regulates lipid metabolism and improves T cell differentiation in sepsis under chronic stress

Study on the mechanism of fibroblast growth factor 21 in patients with sepsis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200064826
Enrollment
Unknown
Registered
2022-10-19
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

control group:none
sepsis group:none
sepsis shock group:none

Sponsors

Xinhua Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Non sepsis patients, sepsis patients and sepsis shock patient; 2. Aged >= 18 years.

Exclusion criteria

Exclusion criteria: 1. Patients who refused to participate in the experiment; 2. Various reasons lead to incomplete data collected at last; 3. Primary liver cancer (such as liver clear cell carcinoma), leukemia, acquired lipodystrophy, systemic lupus erythematosus, psoriasis, rheumatoid arthritis, systemic scleroderma, autoimmune encephalitis, asthma attack and other autoimmune diseases closely related to Th17 and FGF21; 4. Currently, weight loss products, insulin, IL-17 antibody and other drugs are being used.

Design outcomes

Primary

MeasureTime frame
Th17;FGF21;Inflammatory factors;Redox factors;Lymphocyte;T cell;—

Countries

China

Contacts

Public ContactRen Rongrong

Xinhua Hospital, Shanghai Jiaotong University School of Medicine

renrongrong@xinhuamed.com.cn+86 21 25077825

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026